2 news items
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
APLS
24 May 24
., head of R&D and medical affairs, chief medical officer, Sobi. "These findings underscore our conviction in pegcetacoplan's potential to address
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
APLS
7 May 24
.Continued high patient compliance rates of 97%. R&D Highlights
- Prev
- 1
- Next